164 related articles for article (PubMed ID: 20735387)
1. Trends in the treatment of localized prostate cancer using supplemented cancer registry data.
Hamilton AS; Albertsen PC; Johnson TK; Hoffman R; Morrell D; Deapen D; Penson DF
BJU Int; 2011 Feb; 107(4):576-84. PubMed ID: 20735387
[TBL] [Abstract][Full Text] [Related]
2. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
3. A population-based analysis of contemporary patterns of care in younger men (<60 years old) with localized prostate cancer.
Wong AT; Safdieh JJ; Rineer J; Weiner J; Schwartz D; Schreiber D
Int Urol Nephrol; 2015 Oct; 47(10):1629-34. PubMed ID: 26329748
[TBL] [Abstract][Full Text] [Related]
4. Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends.
Tang C; Hoffman KE; Allen PK; Gabel M; Schreiber D; Choi S; Chapin BF; Nguyen QN; Davis JW; Corn P; Logothetis C; Ward J; Frank SJ; Navai N; McGuire SE; Anscher M; Pisters L; Pettaway CA; Kumar R; Linson P; Tripuraneni P; Tomaszewski JJ; Patel AB; Augspurger M; Kuban DA
Cancer; 2020 Feb; 126(3):506-514. PubMed ID: 31742674
[TBL] [Abstract][Full Text] [Related]
5. Racial treatment trends in localized/regional prostate carcinoma: 1992-1999.
Underwood W; Jackson J; Wei JT; Dunn R; Baker E; Demonner S; Wood DP
Cancer; 2005 Feb; 103(3):538-45. PubMed ID: 15612083
[TBL] [Abstract][Full Text] [Related]
6. Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015.
Mahal BA; Butler S; Franco I; Spratt DE; Rebbeck TR; D'Amico AV; Nguyen PL
JAMA; 2019 Feb; 321(7):704-706. PubMed ID: 30743264
[TBL] [Abstract][Full Text] [Related]
7. Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study.
Moschini M; Fossati N; Sood A; Lee JK; Sammon J; Sun M; Pucheril D; Dalela D; Montorsi F; Karnes RJ; Briganti A; Trinh QD; Menon M; Abdollah F
Eur Urol Focus; 2018 Jan; 4(1):68-74. PubMed ID: 28753764
[TBL] [Abstract][Full Text] [Related]
8. Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study.
Hoffman RM; Harlan LC; Klabunde CN; Gilliland FD; Stephenson RA; Hunt WC; Potosky AL
J Gen Intern Med; 2003 Oct; 18(10):845-53. PubMed ID: 14521648
[TBL] [Abstract][Full Text] [Related]
9. A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age.
Terakedis BE; Rossi PJ; Liauw SL; Johnstone PA; Jani AB
Am J Clin Oncol; 2010 Dec; 33(6):619-23. PubMed ID: 20051808
[TBL] [Abstract][Full Text] [Related]
10. Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011.
Evans SM; Millar JL; Davis ID; Murphy DG; Bolton DM; Giles GG; Frydenberg M; Andrianopoulos N; Wood JM; Frauman AG; Costello AJ; McNeil JJ
Med J Aust; 2013 Jun; 198(10):540-5. PubMed ID: 23725268
[TBL] [Abstract][Full Text] [Related]
11. The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer.
Wilt TJ
J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):184-90. PubMed ID: 23271771
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Demographic Factors Associated With Receipt of Non Guideline-concordant Initial Therapy for Nonmetastatic Prostate Cancer.
Hamilton AS; Fleming ST; Wang D; Goodman M; Wu XC; Owen JB; Lo M; Ho A; Anderson RT; Thompson T
Am J Clin Oncol; 2016 Feb; 39(1):55-63. PubMed ID: 24390274
[TBL] [Abstract][Full Text] [Related]
13. Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer.
Gray PJ; Lin CC; Cooperberg MR; Jemal A; Efstathiou JA
Eur Urol; 2017 May; 71(5):729-737. PubMed ID: 27597241
[TBL] [Abstract][Full Text] [Related]
14. Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer.
Muralidhar V; Mahal BA; Butler S; Lamba N; Yang DD; Leeman J; D'Amico AV; Nguyen PL; Trinh QD; Orio PF; King MT
J Urol; 2019 Nov; 202(5):973-978. PubMed ID: 31144590
[TBL] [Abstract][Full Text] [Related]
15. Population-Based Assessment of Determining Treatments for Prostate Cancer.
Chamie K; Williams SB; Hu JC
JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of surgery versus external beam radiation with/without brachytherapy in high-risk localized prostate cancer.
Yin M; Zhao J; Monk P; Martin D; Folefac E; Joshi M; Jin N; Mortazavi A; Verschraegen C; Clinton S
Cancer Med; 2020 Jan; 9(1):27-34. PubMed ID: 31697452
[TBL] [Abstract][Full Text] [Related]
17. Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer.
Shavers VL; Brown M; Klabunde CN; Potosky AL; Davis W; Moul J; Fahey A
Med Care; 2004 Mar; 42(3):239-50. PubMed ID: 15076823
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients.
Bandini M; Preisser F; Nazzani S; Marchioni M; Tian Z; Mazzone E; Graefen M; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Eur Urol Oncol; 2018 Aug; 1(3):215-222. PubMed ID: 31102624
[TBL] [Abstract][Full Text] [Related]
19. Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
Nelson TJ; Javier-DesLoges J; Deka R; Courtney PT; Nalawade V; Mell L; Murphy J; Parsons JK; Rose BS
JAMA Netw Open; 2021 May; 4(5):e219452. PubMed ID: 33999164
[TBL] [Abstract][Full Text] [Related]
20. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR
JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
